New KLAS Analysis report and analysis research carried out with Quest Diagnostics spotlight firm’s buyer and product momentum
Proscia®, a worldwide chief in AI-enabled pathology options for precision medication, has expanded its management place within the diagnostic pathology market. The corporate has grown its medical buyer base by greater than 100% prior to now yr. Amongst its different highlights, Proscia was acknowledged by KLAS Analysis in a June 2024 Emerging Company Spotlight report and launched findings from a study carried out with Quest Diagnostics, a number one supplier of diagnostic info providers, on the affect of its AI-enabled workflows.
Proscia’s momentum comes as digital pathology experiences a brand new surge in world demand. Laboratories are more and more looking for to develop their companies by capitalizing on the real-world information generated within the shift from microscope to pictures; every complete slide picture accommodates over 1 billion pixels that may advance the following blockbuster therapies. With its Concentriq® software program platform, Proscia allows laboratories to totally leverage their information whereas optimizing operations and laying the muse to unlock new insights with AI purposes.
KLAS Rising Firm Highlight confirms Concentriq delivers instant worth and clients belief Proscia
Early information from KLAS reveals nearly all of Proscia’s clients surveyed noticed instant advantages from Concentriq, and all such clients achieved outcomes inside 6 months of deploying the enterprise pathology platform. Impacts cited embody enhancing turnaround occasions, attracting extra expertise, and making a real-world information archive for fueling analysis and growth.
The KLAS report moreover reveals that these clients are impressed with each the extent of assist they obtain and Proscia’s pathology experience. In addition they awarded Proscia an ‘A+’ ranking for its govt staff’s involvement. Working with a trusted accomplice that provides a world-class software program platform has led 100% of Proscia’s clients surveyed to say they might purchase once more.
Learn KLAS Analysis’s Rising Firm Highlight on Concentriq by accessing the total report here.
Quest Diagnostics research highlights Concentriq’s scalable strategy to AI
Utilizing Concentriq’s AI-enabled workflows with Ibex’s clinical-grade, AI-powered Prostate* resolution, pathologists at Quest Diagnostics had been capable of signal out 2.9 circumstances per hour as an alternative of 1.2. The providing was designed to help pathologists in enhancing the detection and grading of prostate most cancers by streamlining pathologists’ assessment of tissue samples which were scanned at excessive decision to create digital slides, or complete slide photographs (WSIs), which pathologists can then view.
The research included 180 randomized prostate circumstances from grownup (21 or older) topics. 100% of the pathologists who participated within the research said they might be more likely to undertake AI on the research’s conclusion. Quest Diagnostics, via its AmeriPath and Dermpath Diagnostics subspecialty pathology companies, employs over 400 pathologists at its nationwide community of medical laboratories.
“We’re thrilled to assist exhibit the affect of AI-driven pathology via this research with Proscia and Ibex Medical Analytics,” mentioned Kristie Dolan, Senior Vice President and Normal Supervisor of Oncology & Pathology at Quest Diagnostics. “The findings present additional proof that pathology is present process an unprecedented transformation, and we are going to proceed to collaborate with world-class corporations to stay on the forefront of this innovation.”
View and obtain the research in its entirety here.
Current FDA clearance allows Proscia to convey its software program to U.S. diagnostic pathology market
In February, Proscia acquired FDA 510(okay) clearance for its Concentriq AP-Dx** resolution for the aim of major prognosis. This milestone not solely opened the U.S. diagnostic pathology market to Proscia but in addition allows its distribution companions Agilent Applied sciences and Siemens Healthineers to offer its software program to their U.S.-based clients.
Proscia’s 510(okay) clearance additional builds on its regulatory credentials. It was the primary firm to obtain CE-IVDR certification to advance digital pathology major prognosis within the European Union and has merchandise licensed in Canada and cleared in the UK amongst different international locations.
“Increasingly laboratories are placing their belief in Proscia to assist them ship quicker outcomes, present assured diagnoses, and develop their companies, particularly now that now we have FDA clearance,” mentioned David West, CEO. “It’s extremely rewarding to see the affect our Concentriq platform and staff are delivering. That is evident from the constructive suggestions our clients shared with KLAS in addition to Quest Diagnostics’ spectacular research outcomes.”
*The Ibex suite contains options that are for Analysis Use Solely (RUO) in the US and never cleared by the FDA. A number of options are CE marked (IVDD and IVDR) and registered with the UK MHRA. For extra info, together with indication to be used and regulatory approval in different international locations, contact Ibex Medical Analytics.
**Concentriq AP-Dx is cleared (K230839) for medical use with the Hamamatsu NanoZoomer S360MD Slide scanner in the US.
Join the free insideAI Information newsletter.
Be part of us on Twitter: https://twitter.com/InsideBigData1
Be part of us on LinkedIn: https://www.linkedin.com/company/insideainews/
Be part of us on Fb: https://www.facebook.com/insideAINEWSNOW